William C Cushman Selected Research

dulaglutide

1/2022	Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial.
1/2021	Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.
1/2021	Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin.
11/2020	Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.
1/2020	The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.
1/2020	Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.
1/2019	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
1/2019	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
1/2018	Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

William C Cushman Research Topics

Disease

40	Hypertension (High Blood Pressure) 01/2022 - 01/2002
39	Type 2 Diabetes Mellitus (MODY) 01/2022 - 01/2002
39	Myocardial Infarction 01/2021 - 11/2002
27	Stroke (Strokes) 01/2022 - 11/2003
27	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 11/2002
24	Heart Failure 01/2022 - 11/2002
11	Acute Coronary Syndrome 10/2018 - 10/2011
7	Isolated Systolic Hypertension 10/2019 - 03/2002
7	Coronary Disease (Coronary Heart Disease) 01/2017 - 11/2002
6	Chronic Renal Insufficiency 01/2021 - 05/2003
6	Diabetes Mellitus 01/2020 - 04/2009
5	Unstable Angina 11/2020 - 10/2013
4	Hypotension (Low Blood Pressure) 01/2021 - 11/2015
4	Acute Kidney Injury (Acute Renal Failure) 01/2021 - 11/2015
4	Syncope (Fainting) 01/2021 - 11/2015
3	Hypoglycemia (Reactive Hypoglycemia) 01/2021 - 03/2011
3	Kidney Diseases (Kidney Disease) 01/2021 - 03/2016
3	Orthostatic Hypotension (Postural Hypotension) 01/2021 - 10/2016
3	Prediabetic State (Prediabetes) 01/2021 - 08/2017
3	Essential Hypertension 01/2018 - 12/2012
3	Chronic Kidney Failure (Chronic Renal Failure) 01/2018 - 05/2009
3	Obesity 02/2017 - 05/2003
2	Atrial Fibrillation 01/2022 - 10/2017
2	Neoplasms (Cancer) 01/2022 - 10/2013
2	Bradycardia 01/2021 - 01/2020
2	Overweight 02/2017 - 02/2017
2	Peripheral Arterial Disease 11/2014 - 09/2006
2	Hypokalemia 12/2012 - 05/2012
2	Albuminuria 05/2012 - 08/2010
2	Dyslipidemias (Dyslipidemia) 07/2010 - 06/2007
2	Sleep Apnea Syndromes (Sleep Apnea) 06/2008 - 06/2008
1	Atrial Flutter (Flutter, Atrial) 01/2022
1	Erectile Dysfunction 01/2021
1	Vascular Diseases (Vascular Disease) 01/2021
1	Cognitive Dysfunction 01/2020
1	Ischemic Stroke 01/2020
1	Body Weight (Weight, Body) 01/2018
1	Headache (Headaches) 09/2017
1	Nasopharyngitis 09/2017
1	Dizziness (Lightheadedness) 09/2017
1	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 12/2016
1	Chronic Disease (Chronic Diseases) 11/2015

Drug/Important Bio-Agent (IBA)

49	Antihypertensive Agents (Antihypertensives)IBA 12/2021 - 03/2002
31	LipidsIBA 10/2017 - 11/2002
25	Chlorthalidone (Chlortalidone)FDA LinkGeneric 01/2022 - 11/2002
22	DiureticsIBA 01/2022 - 11/2002
20	Amlodipine (Norvasc)FDA LinkGeneric 01/2018 - 01/2002
19	Lisinopril (Prinivil)FDA LinkGeneric 01/2018 - 11/2002
15	ThiazidesIBA 01/2022 - 05/2003
14	Hydrochlorothiazide (Esidrix)FDA LinkGeneric 01/2022 - 10/2005
13	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2017 - 11/2002
12	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 06/2005
11	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 01/2017 - 11/2002
9	dulaglutideIBA 01/2022 - 01/2018
9	alogliptinIBA 08/2018 - 10/2011
8	Pharmaceutical PreparationsIBA 01/2021 - 05/2003
5	Hypoglycemic Agents (Hypoglycemics)IBA 01/2020 - 10/2011
5	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2020 - 01/2018
5	azilsartan medoxomilIBA 11/2018 - 08/2012
5	Doxazosin (Cardura)FDA LinkGeneric 02/2013 - 11/2002
4	omega-Chloroacetophenone (Mace)IBA 01/2021 - 05/2015
4	ElectrolytesIBA 01/2021 - 11/2015
4	IncretinsIBA 11/2020 - 01/2018
4	Angiotensin Receptor AntagonistsIBA 11/2018 - 05/2003
4	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 05/2017 - 06/2008
4	Sodium Chloride Symporter Inhibitors (Diuretics, Thiazide)IBA 01/2017 - 12/2003
4	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2016 - 10/2011
4	Irbesartan FDA LinkGeneric 01/2008 - 10/2005
3	hydroxide ionIBA 01/2021 - 10/2016
3	Glucagon-Like Peptide-1 ReceptorIBA 11/2020 - 01/2019
3	Insulin (Novolin)FDA Link 01/2020 - 05/2017
3	Blood Glucose (Blood Sugar)IBA 01/2020 - 08/2010
3	olmesartanIBA 11/2018 - 08/2012
3	CreatinineIBA 09/2017 - 08/2010
3	Valsartan (Vals)FDA Link 04/2012 - 08/2011
2	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2021 - 01/2021
2	Retinaldehyde (Retinal)IBA 01/2018 - 08/2010
2	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 01/2018 - 10/2013
2	CholesterolIBA 02/2017 - 02/2017
2	SodiumIBA 11/2016 - 08/2012
2	Simvastatin (Zocor)FDA LinkGeneric 07/2010 - 04/2010
2	Fenofibrate (CiL)FDA LinkGeneric 07/2010 - 04/2010
2	Fibric Acids (Fibrates)IBA 04/2010 - 06/2007
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 04/2010 - 06/2007
2	Drug CombinationsIBA 06/2008 - 06/2008
2	Losartan (Cozaar)FDA LinkGeneric 11/2003 - 03/2002
1	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2021
1	Metformin (Glucophage)FDA LinkGeneric 01/2021
1	3,5-diisopropylsalicylic acid (DIPS)IBA 01/2019
1	welan (S 130)IBA 10/2018
1	Olmesartan Medoxomil (Votum)FDA Link 09/2017
1	Troponin IIBA 05/2017
1	dipeptidaseIBA 05/2016

Therapy/Procedure

38	Therapeutics 01/2021 - 11/2002
7	Glycemic Control 01/2021 - 06/2007
3	Subcutaneous Injections 01/2019 - 01/2018
2	Light Coagulation 08/2010 - 07/2010
2	Vitrectomy 08/2010 - 07/2010
1	Injections 01/2018
1	Activities of Daily Living (ADL) 11/2015